Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy

Annals of Oncology

Volumn 18, Issue 3, 2007, Pages 522-528

  Bellmunt, J ^a   Paz Ares, L ^b   Cuello, M ^c   Cecere, F L ^c   Albiol, S ^d   Guillem, V ^e   Gallardo, E ^f   Carles, J ^g   Mendez, P ^c   de la Cruz, J J ^h   Taron, M ^c   Rosell, R ^c   Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d HOSPITAL QUIRÓN   (Spain)

^e INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^f Department of Anesthesiology   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Advanced bladder cancer; BRCA1; Caveolin; ERCC1; NER system; RRM1

Indexed keywords

BRCA1 PROTEIN; CAVEOLIN 1; CISPLATIN; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; MESSENGER RNA; PACLITAXEL; PLATINUM DERIVATIVE; RIBONUCLEOTIDE REDUCTASE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER SURVIVAL; DRUG RESPONSE; EXCISION REPAIR; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA;

EID: 33847681504     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl435     Document Type: Article

References (34)

1. von der Maase H, Hansen SW, Roberts JT et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18 (17): 3068-3077.
2. Bellmunt J, Albanell J, Paz-Ares L et al. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 2002; 95 (4): 751-757.
3. Bellmunt J, Guillem V, Paz-Ares L et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J Clin Oncol 2000; 18 (18): 3247-3255.
4. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999; 17 (10): 3173-3181.
5. Geller NL, Sternberg CN, Penenberg D et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991; 67 (6): 1525-1531.
6. Rosell R, Taron M, Ariza A et al. Molecular predictors of response to chemotherapy in lung cancer. Semin Oncol 2004; 31 (1 Suppl 1): 20-27.
7. Britten RA, Liu D, Tessier A et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000; 89 (5): 453-457.
8. Dabholkar M, Vionnet J, Bostick-Bruton F et al Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94 (2): 703-708.
9. Lord RV, Brabender J, Gandara D et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8 (7): 2286-2291.
10. Metzger R, Leichman CG, Danenberg KD et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16 (1): 309-316.
11. Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19 (23): 4298-4304.
12. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355 (10): 983-991.
13. Kennedy RD, Quinn JE, Johnston PG, Harkin DP. BRCA1: Mechanisms of inactivation and implications for management of patients. Lancet 2002; 360 (9338): 1007-1014.
14. Quinn JE, Kennedy RD, Mullan PB et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003; 63 (19): 6221-6228.
15. Taron M, Rosell R, Felip E et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13 (20): 2443-2449.
16. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2004; 10 (4): 1318-1325.
17. Davidson JD, Ma L, Flagella M et al. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004; 64 (11): 3761-3766.
18. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005; 288 (3): C494-C506.
19. Yang CP, Galbiati F, Volonte D et al. Upregulation of caveolin-1 and caveolae organelles in Taxol-resistant A549 cells. FEBS Lett 1998; 439 (3): 368-372.
20. Sunaga N, Miyajima K, Suzuki M et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 2004; 64 (12): 4277-4285.
21. Rosell R, Taron M, Alberola V et al. Genetic testing for chemotherapy in nonsmall cell lung cancer. Lung Cancer 2003; 41 (Suppl 1): S97-S102.
22. Reardon JT, Vaisman A, Chaney SG, Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamineplatinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999; 59 (16): 3968-3971.
23. Li Q, Yu JJ, Mu C et al. Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res 2000; 20 (2A): 645-652.
24. Melton DW KA, Nunez F. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J Cell Sci 1998; 111: 395-404.
25. Metzger R, Schneider PM, Baldus SE. Quantitative ERCC1 RNA expression identifies non-response to cis-platinum based neoadjuvant radiochemotherapy for esophageal cancer. Proc Am Soc Clin Oncol 2001; 20: 130a.
26. Petrylak DP, Scher HI, Reuter V et al. P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. Ann Oncol 1994; 5 (9): 835-840.
27. Pendyala L, Velagapudi S, Toth K et al. Translational studies of glutathione in bladder cancer cell lines and human specimens. Clin Cancer Res 1997; 3 (5): 793-798.
28. Siu LL, Banerjee D, Khurana RJ et al. The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma. Clin Cancer Res 1998; 4 (3): 559-565.
29. Cordon-Cardo C, Sheinfeld J, Dalbagni G. Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol 1997; 13 (5): 319-327.
30. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994; 331 (19): 1259-1264.
31. Sarkis AS, Bajorin DF, Reuter VE et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13 (6): 1384-1390.
32. Edelman MJ, Meyers FJ, Miller TR et al. Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: A well-tolerated regimen with activity independent of p53 mutation. Urology 2000; 55 (4): 521-525.
33. Bellmunt J, Hussain M, Dinney CP. Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 2003; 46 (Suppl): S85-S104.
34. Raghavan D. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer. Cancer 2003; 97 (8 Suppl): 2083-2089.